Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma

Journal of the National Cancer Institute

Volumn 89, Issue 10, 1997, Pages 697-702

  Platz, Anton ^a   Hansson, Johan ^a   Månsson Brahme, Eva ^a   Lagerlöf, Bengt ^a   Linder, Stig ^a   Lundqvist, Eva ^b   Sevigny, Pierre ^b   Inganäs, Mats ^b   Ringborg, Ulrik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b GE Healthcare Bio Sciences AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHROMOSOME 1P; CHROMOSOME 6P; CHROMOSOME 9P; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; SWEDEN;

EID: 0030964344     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.10.697     Document Type: Article

References (35)

1. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Frazer NC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65.
2. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-52.
3. Bale SJ, Dracopoli NC, Tucker MA, Clark WH Jr, Fraser MC, Stanger BZ, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p [published erratum appears in N Engl J Med 1991;324:925]. N Engl J Med 1989;320:1367-72.
4. Goldstein AM, Dracopoli NC, Ho EC, Fraser MC, Kearns KS, Bale SJ, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 1993;52:537-50.
5. Walker GJ, Nancarrow DJ, Walters MK, Palmer JM, Weber JL, Hayward NK. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer 1994;59:771-5.
6. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene 1995;11:211-9.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366: 704-7.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
9. Dracopoli NC, Fountain JW. CDKN2 mutations in melanoma. In: Leigh EM, Newton Bishop JA, Kripke ML, editors. Skin cancer. Cancer surveys, Vol 26. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1996:115-32.
10. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995;146: 1199-206.
11. Platz A, Ringborg U, Lagerlof B, Lundqvist E, Sevigny P, Inganas M. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer 1996;73:344-8.
12. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
13. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
14. Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, et al. Analysis of the p16 gene. CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995;11:2289-94.
15. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995;5:169-77.
16. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995;4:1845-52.
17. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375:506-10.
18. Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995;11:405-12.
19. Reymond A, Brent R. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 1995;11:1173-8.
20. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257-61.
21. Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, Fountain JW. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res 1995;55:5531-5.
22. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995;55:2988-94.
23. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, et al. A novel p16INK4A transcript. Cancer Res 1995;55:2995-7.
24. Duro D, Bernard O, Della Valle V, Berger R, Larsen CJ. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995;11:21-9.
25. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
26. Lagerkvist A, Stewart J, Lagerstrom-Fermer M, Landegren U. Manifold sequencing: efficient processing of large sets of sequencing reactions. Proc Natl Acad Sci U S A 1994;91:2245-9.
27. Mashiyama S, Sekiya T, Hayashi K. Screening of multiple DNA samples for detection of sequence changes. Technique-J Methods Cell Mol Biol 1990;2:304-6.
28. Platz A, Sevigny P, Norberg T, Ring P, Lagerof B, Ringborg U. Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer 1996;74:936-41.
29. Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995;55:1436-40.
30. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, et al. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines [published erratum appears in Oncogene 1995;11:2455]. Oncogene 1995;10:1061-7.
31. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-4.
32. Whelan AJ, Bartsch D, Goodfellow PJ. A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor suppressor gene. N Engl J Med 1995;333:975-7.
33. Borg A, Johansson U, Johannsson O, Hakansson S, Westerdahl J, Masback A, et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res. In press.
34. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4 binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
35. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence of genetic heterogeneity. Am J Hum Genet 1994;54:489-96.